Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Inovio Pharmaceuticals, Inc.    INO


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Inovio Pharmaceuticals, Inc. : Close to a key resistance level

05/22/2020 | 12:02pm EST
05/22/2020 | 12:02pm EST
long trade
Target price hit
Entry price : 14.145$ | Target : 18.5$ | Stop-loss : 10.28$ | Potential : 30.79%
Inovio Pharmaceuticals, Inc. shares are closing in on important technical levels. The technical chart pattern suggests that the currently tested resistance will be broken and new upside potential arises while volatility is likely to increase. Investors could get ahead of this signal in order to benefit from a better risk/reward ratio.
Investors have an opportunity to buy the stock and target the $ 18.5.


Inovio Pharmaceuticals, Inc. : Inovio Pharmaceuticals, Inc. : Close to a key resistance level
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The tendency within the weekly time frame is positive above the technical support level at 5.35 USD

  • Stock prices approach a strong long-term resistance in weekly data at USD 14.59.
  • The stock is close to a major daily resistance at USD 15.79, which should be gotten rid of so as to gain new appreciation potential.
  • Low profitability weakens the company.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

© Zonebourse.com 2020
Stocks mentioned in the article
ChangeLast1st jan.
BEST INC. 2.89% 2.85 Delayed Quote.-48.74%
INOVIO PHARMACEUTICALS, INC. 4.59% 12.52 Delayed Quote.279.39%
THE NEW HOME COMPANY INC. 1.07% 5.67 Delayed Quote.21.67%

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 4,05 M - -
Net income 2020 -181 M - -
Net Debt 2020 - - -
P/E ratio 2020 -10,6x
Yield 2020 -
Capitalization 2 121 M 2 121 M -
Capi. / Sales 2020 523x
Capi. / Sales 2021 14,9x
Nbr of Employees 190
Free-Float 97,8%
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 8
Average target price 13,71 $
Last Close Price 12,52 $
Spread / Highest target 99,7%
Spread / Average Target 9,54%
Spread / Lowest Target -36,1%
EPS Revisions
J. Joseph Kim President, Chief Executive Officer & Director
Simon X. Benito Chairman
Jacqueline E. Shea Chief Operating Officer & Executive Vice President
Peter D. Kies Chief Financial & Accounting Officer
Laurent M. Humeau Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.705.88%62 229
LONZA GROUP AG52.83%45 010
CELLTRION, INC.93.92%42 993
SEAGEN INC.57.68%32 484